Literature DB >> 23148153

Developing therapies for the metabolic syndrome: challenges, opportunities, and… the unknown.

Glenn Matfin.   

Abstract

Metabolic syndrome refers to a clustering of established and emerging cardiovascular disease risk factors within a single individual. The established risk factors, such as obesity, diabetes, dyslipidaemia and hypertension, and other emerging risk factors are closely related to central obesity (especially intra-abdominal adiposity) and insulin resistance. However, debate continues about the very existence of the metabolic syndrome. Despite the controversies, many existing and new therapies are targeting the metabolic syndrome and component risk factors. To date, no therapies have been approved specifically for treating the metabolic syndrome. In this article some of the challenges and opportunities in developing therapies for the metabolic syndrome are discussed.

Entities:  

Keywords:  cardiovascular disease; metabolic syndrome; obesity, type 2 diabetes

Year:  2010        PMID: 23148153      PMCID: PMC3475288          DOI: 10.1177/2042018810375812

Source DB:  PubMed          Journal:  Ther Adv Endocrinol Metab        ISSN: 2042-0188            Impact factor:   3.565


  27 in total

1.  Weighing risks and benefits of liraglutide--the FDA's review of a new antidiabetic therapy.

Authors:  Mary Parks; Curtis Rosebraugh
Journal:  N Engl J Med       Date:  2010-02-17       Impact factor: 91.245

Review 2.  Metabolic syndrome: a solution in search of a problem.

Authors:  Ele Ferrannini
Journal:  J Clin Endocrinol Metab       Date:  2007-02       Impact factor: 5.958

3.  Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial.

Authors:  S Yusuf; P Pais; R Afzal; D Xavier; K Teo; J Eikelboom; A Sigamani; V Mohan; R Gupta; N Thomas
Journal:  Lancet       Date:  2009-03-30       Impact factor: 79.321

4.  Progress and challenges in metabolic syndrome in children and adolescents: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in the Young Committee of the Council on Cardiovascular Disease in the Young; Council on Cardiovascular Nursing; and Council on Nutrition, Physical Activity, and Metabolism.

Authors:  Julia Steinberger; Stephen R Daniels; Robert H Eckel; Laura Hayman; Robert H Lustig; Brian McCrindle; Michele L Mietus-Snyder
Journal:  Circulation       Date:  2009-01-12       Impact factor: 29.690

Review 5.  Obesity and the metabolic syndrome in developing countries.

Authors:  Anoop Misra; Lokesh Khurana
Journal:  J Clin Endocrinol Metab       Date:  2008-11       Impact factor: 5.958

6.  Withdrawal of sibutramine in Europe.

Authors:  Gareth Williams
Journal:  BMJ       Date:  2010-02-09

7.  Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study.

Authors:  Luc F Van Gaal; Aila M Rissanen; André J Scheen; Olivier Ziegler; Stephan Rössner
Journal:  Lancet       Date:  2005 Apr 16-22       Impact factor: 79.321

8.  Genome-wide linkage scan for the metabolic syndrome: the GENNID study.

Authors:  Karen L Edwards; Carolyn M Hutter; Jia Yin Wan; Helen Kim; Stephanie A Monks
Journal:  Obesity (Silver Spring)       Date:  2008-04-17       Impact factor: 5.002

9.  A strategy to reduce cardiovascular disease by more than 80%.

Authors:  N J Wald; M R Law
Journal:  BMJ       Date:  2003-06-28

10.  Effect of a multifactorial intervention on mortality in type 2 diabetes.

Authors:  Peter Gaede; Henrik Lund-Andersen; Hans-Henrik Parving; Oluf Pedersen
Journal:  N Engl J Med       Date:  2008-02-07       Impact factor: 91.245

View more
  2 in total

Review 1.  Natural Polyphenols in Metabolic Syndrome: Protective Mechanisms and Clinical Applications.

Authors:  Shiyao Zhang; Mengyi Xu; Wenxiang Zhang; Chang Liu; Siyu Chen
Journal:  Int J Mol Sci       Date:  2021-06-06       Impact factor: 5.923

2.  Hydroethanolic Extract of Prunus domestica L.: Metabolite Profiling and In Vitro Modulation of Molecular Mechanisms Associated to Cardiometabolic Diseases.

Authors:  Hammad Ullah; Eduardo Sommella; Cristina Santarcangelo; Danilo D'Avino; Antonietta Rossi; Marco Dacrema; Alessandro Di Minno; Giacomo Di Matteo; Luisa Mannina; Pietro Campiglia; Paolo Magni; Maria Daglia
Journal:  Nutrients       Date:  2022-01-14       Impact factor: 5.717

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.